Baseline endemicity level (microfilarial prevalence) | Systematic non-compliance | 80% overall therapeutic coverage | 60% overall therapeutic coverage | ||||
---|---|---|---|---|---|---|---|
Projected duration, in years, of treatment programme (relative cost, in percent) | Projected duration, in years, of treatment programme (relative cost, in percent) | ||||||
aCDTI | bCDTI (ǂ) | aCDTM (ǂ,†) | aCDTI | bCDTI (ǂ) | aCDTM (ǂ,†) | ||
Mesoendemic (40%) | 0.1% | 17 | 11 (113%) | 11 (71%, 63%) | 23 | 14 (108%) | 15 (75%, 70%) |
2.0% | 18 | 13 (124%) | 13 (78%, 63%) | 24 | 15 (133%) | 16 (75%, 66%) | |
5.0% | 20 | 16 (136%) | 16 (85%, 63%) | 26 | 18 (124%) | 19 (80%, 65%) | |
Hyperendemic (60%) | 0.1% | 25 | 16 (116%) | 17 (76%, 66%) | 37 | 19 (104%) | 21 (70%, 67%) |
2.0% | 28 | 19 (123%) | 20 (80%, 65%) | 42 | 22 (108%) | 24 (72%, 66%) | |
5.0% | 32 | 24 (133%) | 24 (83%, 63%) | 49 | 28 (119%) | 29 (76%, 64%) | |
Highly hyperendemic (80%) | 0.1% | NA | 26 (112%) | 26 (70%, 63%) | NA | 38 (140%) | 46 (96%, 69%) |
2.0% | NA | 40 (144%) | 43 (80%, 65%) | NA | NA (160%) | NA (100%, 63%) | |
5.0% | NA | NA (160%) | NA (100%, 63%) | NA | NA (160%) | NA (100%, 63%) |